Pain Management · AnalgesicsRegulatory Approvalregulatorymid-term

Aurobindo Pharma's ANDA218359 for Acetaminophen and Ibuprofen Receives AP Status

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Aurobindo Pharma6 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/23/2026, 6:31:17 AM

Assessment confidence: 46% · The main uncertainty is limited high-relevance corpus coverage for this sub-indication.

Executive Thesis

The FDA's Abbreviated Approval of Aurobindo Pharma's combination product positions the company competitively within the analgesics market. This development could disrupt existing market dynamics and requires close observation of launch strategies and market responses. Regulatory context from FDA (FDA AP — ACETAMINOPHEN AND IBUPROFEN (SUPPL)) supports the near-term read. Assessment grounded in 8 ranked evidence items (1 high-relevance).

Strategic Assessment

The strongest clinical anchor is Clinical Evaluation of the EpiFaith™ Syringe in Epidural Pain Management (ClinicalTrials.gov), sub-indication match (pain). In pain, 1 regulatory and 4 competitive items passed relevance filtering for Aurobindo Pharma. Aurobindo's entry with this combination product may capture market share from established brands, potentially affecting revenue streams for competitors in the analgesics space.

Competitive Pressure

The most relevant competitive pressure comes from [Ad hoc announcement pursuant to Art. (Roche) — sponsor/company relevance (roche). Secondary pressure from Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217). This approval may enhance Aurobindo's position in the competitive analgesics market, particularly against established brands.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — ACETAMINOPHEN AND IBUPROFEN (SUPPL) (FDA). Entity match (aurobindo pharma); Regulatory pathway relevance (nda). The AP status indicates a streamlined pathway for Aurobindo's product, which could influence future regulatory strategies for similar combination therapies.

Key Risks

Elevated medium regulatory exposure for Aurobindo Pharma could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Aurobindo's entry with this combination product may capture market share from established brands, potentially affecting revenue streams for competitors in the analgesics space.
The potential market entry of this combination product and its impact on existing analgesic offerings.

What Would Change This Assessment

This becomes more urgent if Monitor for any further developments regarding the launch timeline and market strategy for ANDA218359.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — ACETAMINOPHEN AND IBUPROFEN (SUPPL)
FDAmedium relevance
Entity match (aurobindo pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — HYDROCODONE BITARTRATE AND ACETAMINOPHEN (SUPPL)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — HYDROCODONE BITARTRATE AND ACETAMINOPHEN (SUPPL)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — HYDROCODONE BITARTRATE AND ACETAMINOPHEN (SUPPL)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — HYDROCODONE BITARTRATE AND ACETAMINOPHEN (SUPPL)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — OXYCODONE AND ACETAMINOPHEN (SUPPL)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — HYDROCODONE BITARTRATE AND ACETAMINOPHEN (SUPPL)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE (SUPPL)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View source

Clinical Evaluation of the EpiFaith™ Syringe in Epidural Pain Management
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Comparison of Two Dosing Regimens of Intravenous Ketorolac for Post-Cesarean Pain Control
ClinicalTrials.govmedium relevance
Sub-indication match (pain)
FDA document
View source
Pre-incisional Infiltration With Ropivacaine Plus Triamcinolone for Relieving Postoperative Pain After Thoracoscopic Surgery
ClinicalTrials.govmedium relevance
Sub-indication match (pain)
FDA document
View source
Low Dose Naltrexone Therapy for Complex Regional Pain Syndrome
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Dulce Digital 2.0 - Innovative Diabetes Self-Management in the Digital Age
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Status Epilepticus Population Study (STEPS)
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
A Prospective Study to Evaluate the Efficacy of Iovera Lumbar Medial Branch Cryoneurolysis Versus Radiofrequency Ablation for the Treatment of Chronic Low Back Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

[Ad hoc announcement pursuant to Art.
Rochemedium relevance
Sponsor/company relevance (Roche)
FDA document
View source
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochemedium relevance
Sponsor/company relevance (Roche)
FDA document
View source
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochemedium relevance
Sponsor/company relevance (Roche)
FDA document
View source
Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)
FDA Approves Tzield for Pediatric Stage 3 Type I Diabetes
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Lavandula angustifolia as a dual pharmacological system: from essential oil to polyphenol-rich biomass.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Factors predicting health-enhancing physical activity in patients with chronic widespread pain following a person-centred health plan.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Two-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Aurobindo Pharma

Commercial impact

medium

Aurobindo's entry with this combination product may capture market share from established brands, potentially affecting revenue streams for competitors in the analgesics space.

Regulatory impact

medium

The AP status indicates a streamlined pathway for Aurobindo's product, which could influence future regulatory strategies for similar combination therapies.

What to watch

Monitor for any further developments regarding the launch timeline and market strategy for ANDA218359.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.